Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Open Access

Pathogenic germline variants in a racially diverse real-world cohort of prostate cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

TCTaylor CrawfordMTMaliha TayebEBEmanuel Barrett

Discussion

Loading...

Member takes

Overview

Cohort analysis identifies a 5.4% PGV rate in prostate cancer patients, suggesting genetic testing guidelines for diverse populations.

Key Points

  • 5.4% of prostate cancer patients had pathogenic germline variants, indicating lower rates compared to academic studies.
  • The study involved 4634 patients, revealing no significant differences in PGV rates based on race or ethnicity.
  • Assessment included various clinical and familial factors, with age and self-identified race linked to PGV presence.
  • Findings support the need for universal genetic testing in patients with aggressive prostate cancer, aligning with NCCN guidelines.

Cite This Study

Crawford et al. (2025) studied this question.

synapsesocial.com/papers/68af3e3ccf1dd9ea359eaeb6https://doi.org/10.1101/2025.08.13.25333614
View Full Paper
Ask AI
Bookmark
Share